{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:58Z","timestamp":1791492718488,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4032729"],"award-info":[{"award-number":["4032729"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.compbiolchem.2026.109458","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:41:40Z","timestamp":1790750500000},"page":"109458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Integrated computational framework for drug repurposing in metastatic prostate cancer using transcriptomic meta-analysis, machine learning, and molecular modeling"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-3260","authenticated-orcid":false,"given":"Javad","family":"Rafiee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Tahereh","family":"Arabi Baygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamid","family":"Aghaee-Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12894-024-01521-9","article-title":"silico exploration of anti-prostate cancer compounds from differential expressed genes","volume":"24","author":"Ajiboye","year":"2024","journal-title":"BMC Urol."},{"issue":"22","key":"10.1016\/j.compbiolchem.2026.109458_bib2","doi-asserted-by":"crossref","first-page":"12441","DOI":"10.3390\/ijms252212441","article-title":"Drug repurposing for cancer treatment: a comprehensive review","volume":"25","author":"Al Khzem","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.kjs.2026.100606","article-title":"Exploring drug repurposing for SGK1 inhibition: FDA-approved drugs and structural insights for new therapeutic strategies","author":"Alrouji","year":"2026","journal-title":"Kuwait J. Sci."},{"issue":"2","key":"10.1016\/j.compbiolchem.2026.109458_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"20","key":"10.1016\/j.compbiolchem.2026.109458_bib5","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.3390\/cancers13205158","article-title":"A unified transcriptional, pharmacogenomic, and gene dependency approach to decipher the biology, diagnostic markers, and therapeutic targets associated with prostate cancer metastasis","volume":"13","author":"Bacolod","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/medsci10010015","article-title":"Overcoming drug resistance in advanced prostate cancer by drug repurposing","volume":"10","author":"Bahmad","year":"2022","journal-title":"Med. Sci."},{"issue":"17","key":"10.1016\/j.compbiolchem.2026.109458_bib7","doi-asserted-by":"crossref","DOI":"10.12968\/bjon.2025.0423","article-title":"Men and cancer: it's time for national and global action","volume":"34","author":"Baker","year":"2025","journal-title":"Br. J. Nurs."},{"issue":"4","key":"10.1016\/j.compbiolchem.2026.109458_bib8","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.3390\/ijms24043135","article-title":"Identification of promising drug candidates against prostate cancer through computationally-driven drug repurposing","volume":"24","author":"Bernal","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.compbiolchem.2026.109458_bib9","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a Cancer J. Clin."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1400029","article-title":"silico approaches for drug repurposing in oncology: a scoping review","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.compbiolchem.2026.109458_bib11","article-title":"ACS report shows prostate cancer remains a signi? cant public health challenge","volume":"53","author":"CLARKE","year":"2025","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.compbiolchem.2026.109458_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2024.07.013","article-title":"Systemic treatments for metastatic prostate cancer in 2024","volume":"10","author":"Gizzi","year":"2024","journal-title":"Eur. Urol. Focus."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.106671","article-title":"Computational drug repurposing by exploiting large-scale gene expression data: strategy, methods and applications","volume":"155","author":"He","year":"2023","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40360-025-00983-3","article-title":"Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer","volume":"26","author":"Irham","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib15","series-title":"Seminars in cancer biology","article-title":"Machine and deep learning approaches for cancer drug repurposing","year":"2021"},{"issue":"14","key":"10.1016\/j.compbiolchem.2026.109458_bib16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2174\/1871530323666230303092243","article-title":"Mitotic kinase inhibitors as therapeutic interventions for prostate cancer: evidence from in vitro studies","volume":"23","author":"Javed","year":"2023","journal-title":"Endocrine Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune Endocrine & Metabolic Disorders)"},{"issue":"6","key":"10.1016\/j.compbiolchem.2026.109458_bib17","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib18","doi-asserted-by":"crossref","first-page":"24992","DOI":"10.17161\/sjm.v3i1.24992","article-title":"Prostate cancer: etiology, diagnosis, and treatment","volume":"3","author":"Li","year":"2026","journal-title":"Serican J. Med."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib19","article-title":"The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Public. Health"},{"issue":"4","key":"10.1016\/j.compbiolchem.2026.109458_bib20","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.3390\/ijms24044154","article-title":"Pharmacological efficacy of repurposing drugs in the treatment of prostate cancer","volume":"24","author":"Louren\u00e7o","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acsomega.2c05821","article-title":"Drug repurposing: a new hope in drug discovery for prostate cancer","volume":"8","author":"Malik","year":"2022","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.compbiolchem.2026.109458_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"issue":"40","key":"10.1016\/j.compbiolchem.2026.109458_bib23","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.2174\/0929867328666210525162730","article-title":"Developing novel drug candidates and repurposed drugs for prostate cancer based on molecular profiles","volume":"28","author":"Mokou","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"7","key":"10.1016\/j.compbiolchem.2026.109458_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1264808","article-title":"Computational identification of potential inhibitors targeting cdk1 in colorectal cancer","volume":"11","author":"Ogbodo","year":"2023","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108329","article-title":"Drug repositioning in castration-resistant prostate cancer using systems biology and computational drug design techniques","volume":"115","author":"Rafiee","year":"2025","journal-title":"Comput. Biol. Chem."},{"issue":"16","key":"10.1016\/j.compbiolchem.2026.109458_bib28","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib29","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.compbiolchem.2026.109458_bib30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.compbiolchem.2026.109458_bib31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur. Urol."},{"issue":"38","key":"10.1016\/j.compbiolchem.2026.109458_bib32","first-page":"39873","article-title":"Discovery of potential inhibitors of CDK1 by integrating pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation studies, and evaluation of their inhibitory activity","volume":"9","author":"Teotia","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.compbiolchem.2026.109458_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fphys.2018.00500","article-title":"Drug repositioning for effective prostate cancer treatment","volume":"9","author":"Turanli","year":"2018","journal-title":"Front. Physiol."},{"issue":"22","key":"10.1016\/j.compbiolchem.2026.109458_bib34","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4161\/cc.5.22.3463","article-title":"Cell cycle synchronization at the G2\/M phase border by reversible inhibition of CDK1","volume":"5","author":"Vassilev","year":"2006","journal-title":"Cell. Cycle"},{"issue":"28","key":"10.1016\/j.compbiolchem.2026.109458_bib35","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.0600447103","article-title":"Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1","volume":"103","author":"Vassilev","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.compbiolchem.2026.109458_bib36","first-page":"44","article-title":"SIU-ICUD: Epidemiology of prostate cancer","volume":"6","author":"Vieira Lima Aguiar Mel\u00e3o","year":"2025","journal-title":"Soci. \u00e9t\u00e9 Int. D. \u2019Urol. J."},{"issue":"16","key":"10.1016\/j.compbiolchem.2026.109458_bib37","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13062-024-00494-x","article-title":"Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches","volume":"19","author":"Wang","year":"2024","journal-title":"Biol. Direct"},{"issue":"14","key":"10.1016\/j.compbiolchem.2026.109458_bib39","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.7150\/thno.25487","article-title":"Blocking CDK1\/PDK1\/\u03b2-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.compbiolchem.2026.109458_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","article-title":"The treatment landscape of metastatic prostate cancer","volume":"519","author":"Yamada","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109458_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12539-021-00487-8","article-title":"Machine learning applications in drug repurposing","volume":"14","author":"Yang","year":"2022","journal-title":"Interdiscip. Sci. Comput. Life Sci."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927126005852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927126005852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:46:17Z","timestamp":1791492377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476927126005852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":42,"alternative-id":["S1476927126005852"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.109458","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated computational framework for drug repurposing in metastatic prostate cancer using transcriptomic meta-analysis, machine learning, and molecular modeling","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.109458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109458"}}